Evidence map›Paper›PMID 27958337›Full record

Trial reportScientific reports2016

Type 2 diabetes mellitus is associated with increased risks of sarcopenia and pre-sarcopenia in Chinese elderly.

Taotao Wang, Xiao Feng, Jingjing Zhou, Hongyan Gong, Song Xia, Qing Wei, Xu Hu, Ran Tao, Lei Li, Frank Qian and 1 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
138citing papers in PubMed, 9 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

138 citing papers in PubMed, 9 syntheses or guidelines pooled it, 249 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Prevalence of Sarcopenia Among the Elderly in Korea: A Meta-Analysis.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2021
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2023
    Trial
  13. Trial
  14. Article
  15. Article
  16. Observational
  17. Review
  18. Article
  19. Article
  20. Article

78 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Taotao WangDepartment of Endocrinology and Clinical Nutrition, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Xiao FengDepartment of Endocrinology and Clinical Nutrition, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Jingjing ZhouDepartment of Endocrinology and Clinical Nutrition, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Hongyan GongDepartment of Endocrinology and Clinical Nutrition, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Song XiaDepartment of Endocrinology and Clinical Nutrition, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Qing WeiJiangsu University Library, Zhenjiang, China.
Xu HuDepartment of Endocrinology and Clinical Nutrition, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Ran TaoDepartment of Endocrinology and Clinical Nutrition, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Lei LiDepartment of Endocrinology and Clinical Nutrition, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Frank QianPritzker School of Medicine, University of Chicago, USA.
Li YuDepartment of Endocrinology and Clinical Nutrition, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Affiliated Hospital of Jiangsu University · CNJiangsu University · CNUniversity of Chicago · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcopenia is a condition characterized by progressive and generalized loss of skeletal muscle mass and function. In this study, we used a cross-sectional study with 1090 community-dwelling Chinese citizens aged 60 years and older to evaluate the association of type 2 diabetes mellitus (T2DM) with the risk of sarcopenia and pre-sarcopenia. Sarcopenia was defined using the Asian Working Group for Sarcopenia (AWGS) criteria that include both muscle mass and muscle function/physical activity. Pre-sarcopenia was defined as having low skeletal muscle index but with normal muscle/physical activity. The prevalence of sarcopenia and pre-sarcopenia was significantly higher in T2DM patients than in healthy controls (14.8% vs. 11.2%, p = 0.035 for sarcopenia, and 14.4% vs. 8.4%, p = 0.002 for pre-sarcopenia). In multivariate logistic regression analyses adjusting by age, gender, anti-diabetic medication, energy intake, protein intake, physical activity, and visceral fat area, we found that Chinese elderly with T2DM exhibited significantly increased risks of sarcopenia (OR = 1.37, 95% CI = 1.02-2.03) and pre-sarcopenia (OR = 1.73, 95% CI = 1.10-2.83) compared to non-diabetic individuals. This is the first study to evaluate the association of T2DM with the risks of sarcopenia and pre-sarcopenia in China. Among a group of community-dwelling Chinese elderly, T2DM was significantly associated with increased risks of sarcopenia and pre-sarcopenia.

Indexed as

AgedAged, 80 and overAge FactorsAsian PeopleChinaDiabetes ComplicationsDiabetes Mellitus, Type 2FemaleHumansMaleMiddle AgedRisk FactorsSarcopenia

Identifiers

PMID27958337
PMCPMC5153616
OpenAlexW2563580879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.